ByTrending Posts
Is AI Now Shaping the Future of Biopharma…
Executive Summary A recent Endpoints Signal Pulse Report reveals that half of biopharma professionals now consider themselves heavy…
Is Butterfly Network Using AI and Handheld Imaging…
Executive Summary Butterfly Network is pioneering AI-enabled, handheld ultrasound devices designed to make imaging more accessible, affordable, and…
Is Canon Medical Systems Using AI to Transform…
Executive Summary Canon Medical Systems is advancing the integration of artificial intelligence, automated analytics, and cloud-enabled imaging solutions…
Is Siemens Healthineers Using AI to Transform Diagnostics,…
Executive Summary Siemens Healthineers, a global leader in medical technology, is accelerating the adoption of AI-driven solutions across…
Can GE Healthcare Integrate AI Across Imaging, Monitoring,…
Headline Summary GE Healthcare, a global leader in medical technology, is driving the next wave of healthcare innovation…
Is Philips Leveraging AI and Connected Care to…
Executive Summary Philips, a global leader in health technology, is accelerating the integration of artificial intelligence, advanced analytics,…
Can CMR Surgical’s AI-Driven Versius Platform Expand Access…
Executive Summary CMR Surgical, the global medical robotics innovator behind the Versius® surgical system, is advancing the integration…
Is Stryker Advancing AI-Enabled Surgical Platforms to Transform…
Executive Summary Stryker, a global leader in medical technology, is accelerating the integration of artificial intelligence, robotics, and…
Can Johnson & Johnson’s Verb Surgical and Ottava…
Executive Summary Johnson & Johnson’s surgical technology efforts—anchored in the Verb Surgical initiative and now evolving under the…
Trending Posts
Latest Stories
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22 Trial, Unleashing Multi-Oncology Disruption
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO…
Gallery
